IP Library › Patent Application 17278397
Patent Application Utility PCT National Stage
App. No. 17/278,397 · Confirmation No. 9475

NOVEL QUINAZOLINE EGFR INHIBITORS

Abandoned -- Failure to Respond to an Office Action View Publication ↗
⬇ PDF
 Code Description Pages PDF
2024-07-11 ABN Abandonment 2 View
2023-11-07 CTRS Requirement for Restriction/Election 9 View
2022-01-24 OATH Oath or Declaration filed 1 View
2022-01-24 N417 Electronic Filing System Acknowledgment Receipt 2 View
2021-11-18 NTC.PUB Notice of Publication 1 View
2021-08-10 WFEE Fee Worksheet (SB06) 1 View
2021-08-10 APP.FILE.REC Filing Receipt 3 View
2021-08-10 WCLM Claims Worksheet (PTO-2022) 1 View
2021-08-10 M903 Notice of Designated Office (DO) / Elected Office (EO) Acceptance Mailed 1 View
2021-03-22 CLM Claims 6 View
2021-03-22 ABST Abstract 1 View
2021-03-22 FRPR Certified Copy of Foreign Priority Application 41 View
2021-03-22 SPEC Specification 21 View
2021-03-22 P.N.101.CONV PCT/RO/101 - Request form for new International Application - Conventional 5 View
2021-03-22 IDS Information Disclosure Statement (IDS) Form (SB08) 4 View
2021-03-22 FOR Foreign Reference 46 View
2021-03-22 WFEE Fee Worksheet (SB06) 2 View
2021-03-22 N417 Electronic Filing System Acknowledgment Receipt 3 View
2021-03-22 TRNA Transmittal of New Application 3 View
2021-03-22 ADS Application Data Sheet 8 View
2021-03-22 A.PE Preliminary Amendment 1 View
2021-03-22 CLM Claims 7 View
2021-03-22 REM Applicant Arguments/Remarks Made in an Amendment 1 View
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this application's details
Quick Facts
App. No.
17/278,397
Filed
2021-03-22
Pub. No.
US20210353627A1
Art Unit
1621